Cefuroxime
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
- Cefuroxime
- Pharmacist Assessment Report
- Cefuroxime: beta-lactam cell-wall synthesis inhibitor (second-generation cephalosporin) → hyperamylasemia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Cefuroxime: beta-lactam cell-wall synthesis inhibitor (second-generation cephalosporin) → hyperamylasemia
One-Sentence Summary
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell-wall synthesis. The TxGNN model predicts it may be associated with hyperamylasemia, but no clinical trials and no publications were found for this disease, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | hyperamylasemia |
| TxGNN Prediction Score | 0.9976 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Cefuroxime belongs to the beta-lactam class of antibiotics, which act by blocking bacterial cell-wall synthesis.
This mechanism has no known connection to amylase metabolism. Nothing suggests that an antibacterial agent would change serum amylase levels or treat a condition defined by raised amylase. The score is a model-based prediction only, likely reflecting proximity in a network of biomedical relationships rather than a real biological effect. We therefore regard the mechanistic rationale as absent.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Cefuroxime is marketed in India. The data compiled for this report list 20 valid licences, all for single-ingredient products and none cancelled; this list may be partial. The licence records carry no approved-indication text. Products come as tablets, syrup, dry syrup and powder for injection.
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 49401 | Cefuset 250mg Tablet | Strip of 10 tablets | Not recorded |
| 93293 | Furix 250mg Tablet | Strip of 10 tablets | Not recorded |
| 146188 | Mutum 250mg Tablet | Strip of 10 tablets | Not recorded |
| 54213 | Cefumex 250mg Tablet | Strip of 10 tablets | Not recorded |
| 191766 | Relicef 1.5gm Injection | Vial of 1 powder for injection | Not recorded |
Safety Considerations
- Drug Interactions: 143 interactions were recorded. Those listed are of moderate level, including:
- Acid-lowering agents: famotidine, ranitidine, cimetidine, nizatidine, omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole, dexlansoprazole
- Antacids: aluminium hydroxide, calcium carbonate, magnesium hydroxide, magnesium oxide, magnesium carbonate, magaldrate
- Aminoglycosides: kanamycin, neomycin
- Others: balsalazide
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported by no clinical trials or publications, and there is no plausible mechanism linking cefuroxime to hyperamylasemia. Evidence level is L5.
To proceed, the following is needed:
- Any clinical or mechanistic evidence directly studying cefuroxime in hyperamylasemia
- Mechanism of action data and package insert warnings and contraindications for cefuroxime
- A clear clinical rationale for why a drug of this class would be used for this condition
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.